{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:00:01Z","timestamp":1790964001699,"version":"4.1.0"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Our previous study revealed that Vav3 oncogene is overexpressed in human prostate cancer, activates androgen receptor (AR), and stimulates growth in prostate cancer cells. The purpose of this study is to further determine the potential role of Vav3 in prostate cancer development in genetically engineered mouse model. We generated Vav3 transgenic mice by targeted overexpression of a constitutive active Vav3 in the prostatic epithelium. We found that overexpression of Vav3 led to development of mouse prostatic intraepithelial neoplasia and prostate cancer at the age of as early as 3 months. The AR signaling axis and phosphatidylinositol 3-kinase-Akt signaling were elevated in the prostate glands of Vav3 transgenic mice. In addition to prostate cancer, Vav3 transgenic mice developed significant nonbacterial chronic prostatitis in the prostate gland with notable infiltration of lymphomononuclear cells (monocytes, lymphocytes, and plasma cells), which was associated with elevated incidence of prostate cancer. DNA microarray and signaling pathway analysis revealed that the top diseases and disorders were inflammatory diseases and cancer of the prostate gland in Vav3 transgenic mice. In vitro analysis showed that overexpression of Vav3 in prostate cancer cells enhanced nuclear factor-\u03baB (NF-\u03baB) activity, implicating an underlying mechanism of innate inflammatory response induced by elevated Vav3 activity. These data showed that Vav3 overexpression in the prostate epithelium enhanced both the AR signaling axis and NF-\u03baB\u2013mediated pathway, which potentially contributed to the development of nonbacterial prostatitis and prostate cancer. [Cancer Res 2008;68(15):6396\u2013406]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0645","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T13:58:13Z","timestamp":1217599093000},"page":"6396-6406","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer"],"prefix":"10.1158","volume":"68","author":[{"given":"Yin","family":"Liu","sequence":"first","affiliation":[{"name":"1Pathology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Qin","family":"Mo","sequence":"additional","affiliation":[{"name":"1Pathology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiande","family":"Hu","sequence":"additional","affiliation":[{"name":"2Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Boivin","sequence":"additional","affiliation":[{"name":"1Pathology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Levin","sequence":"additional","affiliation":[{"name":"3Environmental Heath, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[{"name":"2Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianer","family":"Yang","sequence":"additional","affiliation":[{"name":"2Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyun","family":"Dong","sequence":"additional","affiliation":[{"name":"2Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[{"name":"1Pathology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"2022061700300555100_B1","doi-asserted-by":"crossref","unstructured":"Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell\u20082006; 124: 823\u201335.","DOI":"10.1016\/j.cell.2006.02.016"},{"key":"2022061700300555100_B2","doi-asserted-by":"crossref","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature\u20082002; 420: 860\u20137.","DOI":"10.1038\/nature01322"},{"key":"2022061700300555100_B3","doi-asserted-by":"crossref","unstructured":"De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer\u20082007; 7: 256\u201369.","DOI":"10.1038\/nrc2090"},{"key":"2022061700300555100_B4","doi-asserted-by":"crossref","unstructured":"Karin M, Greten FR. NF-\u03baB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol\u20082005; 5: 749\u201359.","DOI":"10.1038\/nri1703"},{"key":"2022061700300555100_B5","doi-asserted-by":"crossref","unstructured":"Karin M. Nuclear factor-\u03baB in cancer development and progression. Nature\u20082006; 441: 431\u20136.","DOI":"10.1038\/nature04870"},{"key":"2022061700300555100_B6","doi-asserted-by":"crossref","unstructured":"Fan S, Gao M, Meng Q, et al. Role of NF-\u03baB signaling in hepatocyte growth factor\/scatter factor-mediated cell protection. Oncogene\u20082005; 24: 1749\u201366.","DOI":"10.1038\/sj.onc.1208327"},{"key":"2022061700300555100_B7","doi-asserted-by":"crossref","unstructured":"Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-\u03baB activation induced via interaction between Akt and I\u03baB kinase-\u03b2 in breast cancer cells. Oncogene\u20082005; 24: 5482\u201391.","DOI":"10.1038\/sj.onc.1208713"},{"key":"2022061700300555100_B8","doi-asserted-by":"crossref","unstructured":"Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-\u03baB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene\u20082003; 22: 4702\u20139.","DOI":"10.1038\/sj.onc.1206583"},{"key":"2022061700300555100_B9","doi-asserted-by":"crossref","unstructured":"Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol\u20082000; 20: 1461\u201377.","DOI":"10.1128\/MCB.20.5.1461-1477.2000"},{"key":"2022061700300555100_B10","doi-asserted-by":"crossref","unstructured":"Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene\u20082001; 20: 6372\u201381.","DOI":"10.1038\/sj.onc.1204780"},{"key":"2022061700300555100_B11","doi-asserted-by":"crossref","unstructured":"Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J\u20081989; 8: 2283\u201390.","DOI":"10.1002\/j.1460-2075.1989.tb08354.x"},{"key":"2022061700300555100_B12","doi-asserted-by":"crossref","unstructured":"Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol\u20082006; 26: 4830\u201342.","DOI":"10.1128\/MCB.02215-05"},{"key":"2022061700300555100_B13","doi-asserted-by":"crossref","unstructured":"Tamas P, Solti Z, Bauer P, et al. Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem\u20082003; 278: 5163\u201371.","DOI":"10.1074\/jbc.M207555200"},{"key":"2022061700300555100_B14","doi-asserted-by":"crossref","unstructured":"Zeng L, Sachdev P, Yan L, et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol\u20082000; 20: 9212\u201324.","DOI":"10.1128\/MCB.20.24.9212-9224.2000"},{"key":"2022061700300555100_B15","doi-asserted-by":"crossref","unstructured":"Sachdev P, Zeng L, Wang LH. Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J Biol Chem\u20082002; 277: 17638\u201348.","DOI":"10.1074\/jbc.M111575200"},{"key":"2022061700300555100_B16","doi-asserted-by":"crossref","unstructured":"Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med\u20081995; 332: 1393\u20138.","DOI":"10.1056\/NEJM199505253322101"},{"key":"2022061700300555100_B17","doi-asserted-by":"crossref","unstructured":"Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet\u20081995; 9: 401\u20136.","DOI":"10.1038\/ng0495-401"},{"key":"2022061700300555100_B18","doi-asserted-by":"crossref","unstructured":"Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res\u20082005; 65: 7976\u201383.","DOI":"10.1158\/0008-5472.CAN-04-4076"},{"key":"2022061700300555100_B19","unstructured":"Wen Y, Hu MC, Makino K, et al. HER-2\/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res\u20082000; 60: 6841\u20135."},{"key":"2022061700300555100_B20","doi-asserted-by":"crossref","unstructured":"Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase. Nat Med\u20081999; 5: 280\u20135.","DOI":"10.1038\/6495"},{"key":"2022061700300555100_B21","doi-asserted-by":"crossref","unstructured":"Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2\/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A\u20081999; 96: 5458\u201363.","DOI":"10.1073\/pnas.96.10.5458"},{"key":"2022061700300555100_B22","doi-asserted-by":"crossref","unstructured":"Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal\u20082003; 15: 355\u201366.","DOI":"10.1016\/S0898-6568(02)00115-8"},{"key":"2022061700300555100_B23","doi-asserted-by":"crossref","unstructured":"Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst\u20082000; 92: 1918\u201325.","DOI":"10.1093\/jnci\/92.23.1918"},{"key":"2022061700300555100_B24","doi-asserted-by":"crossref","unstructured":"Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A\u20081998; 95: 5246\u201350.","DOI":"10.1073\/pnas.95.9.5246"},{"key":"2022061700300555100_B25","unstructured":"Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN\/MMAC1 in primary prostate cancer. Cancer Res\u20081997; 57: 4997\u20135000."},{"key":"2022061700300555100_B26","doi-asserted-by":"crossref","unstructured":"Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology\u20082001; 142: 4795\u2013805.","DOI":"10.1210\/endo.142.11.8467"},{"key":"2022061700300555100_B27","unstructured":"Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res\u20081998; 58: 2720\u20133."},{"key":"2022061700300555100_B28","doi-asserted-by":"crossref","unstructured":"Lu S, Ren CX, Liu Y, Epner DE. The PI3K-Akt signaling is involved in regulation of p21WAF\/CIP expression and androgen-independent growth in prostate cancer cells. Int J Oncol\u20082006; 28: 245\u201351.","DOI":"10.3892\/ijo.28.1.245"},{"key":"2022061700300555100_B29","doi-asserted-by":"crossref","unstructured":"Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell\u20082003; 4: 209\u201321.","DOI":"10.1016\/S1535-6108(03)00215-0"},{"key":"2022061700300555100_B30","doi-asserted-by":"crossref","unstructured":"Dong ZY, Liu Y, Lu S, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endo\u20082006; 20: 2315\u201325.","DOI":"10.1210\/me.2006-0048"},{"key":"2022061700300555100_B31","doi-asserted-by":"crossref","unstructured":"Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol\u20082006; 20: 1061\u201372.","DOI":"10.1210\/me.2005-0346"},{"key":"2022061700300555100_B32","unstructured":"Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res\u20081996; 56: 4096\u2013102."},{"key":"2022061700300555100_B33","doi-asserted-by":"crossref","unstructured":"Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology\u20082000; 141: 4698\u2013710.","DOI":"10.1210\/endo.141.12.7837"},{"key":"2022061700300555100_B34","doi-asserted-by":"crossref","unstructured":"Lu S, Tsai SY, Tsai MJ. Melecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology\u20081999; 140: 5054\u20139.","DOI":"10.1210\/endo.140.11.7086"},{"key":"2022061700300555100_B35","doi-asserted-by":"crossref","unstructured":"Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.","DOI":"10.2202\/1544-6115.1027"},{"key":"2022061700300555100_B36","doi-asserted-by":"crossref","unstructured":"Sartor M, Schwanekamp J, Halbleib D, et al. Microarray results improve significantly as hybridization approaches equilibrium. Biotechniques\u20082004; 36: 790\u20136.","DOI":"10.2144\/04365ST02"},{"key":"2022061700300555100_B37","doi-asserted-by":"crossref","unstructured":"Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD, Medvedovic M. Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics\u20082006; 7: 538.","DOI":"10.1186\/1471-2105-7-538"},{"key":"2022061700300555100_B38","doi-asserted-by":"crossref","unstructured":"Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int\u20082001; 87: 797\u2013805.","DOI":"10.1046\/j.1464-410x.2001.02193.x"},{"key":"2022061700300555100_B39","doi-asserted-by":"crossref","unstructured":"Penna G, Amuchastegui S, Cossetti C, et al. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol\u20082007; 179: 1559\u201367.","DOI":"10.4049\/jimmunol.179.3.1559"},{"key":"2022061700300555100_B40","doi-asserted-by":"crossref","unstructured":"Bozic CR, Kolakowski LF, Jr., Gerard NP, et al. Expression and biologic characterization of the murine chemokine KC. J Immunol\u20081995; 154: 6048\u201357.","DOI":"10.4049\/jimmunol.154.11.6048"},{"key":"2022061700300555100_B41","doi-asserted-by":"crossref","unstructured":"Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-\u03baB\/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia\u20082004; 6: 390\u2013400.","DOI":"10.1593\/neo.04112"},{"key":"2022061700300555100_B42","doi-asserted-by":"crossref","unstructured":"Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-\u03baB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer\u20082005; 93: 1019\u201323.","DOI":"10.1038\/sj.bjc.6602796"},{"key":"2022061700300555100_B43","doi-asserted-by":"crossref","unstructured":"Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-\u03baB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-\u03baB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res\u20082006; 12: 5578\u201386.","DOI":"10.1158\/1078-0432.CCR-05-2767"},{"key":"2022061700300555100_B44","unstructured":"Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease. Philadelphia: WB Saunders Company; 1999."},{"key":"2022061700300555100_B45","doi-asserted-by":"crossref","unstructured":"Penna G, Amuchastegui S, Cossetti C, et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol\u20082006; 177: 8504\u201311.","DOI":"10.4049\/jimmunol.177.12.8504"},{"key":"2022061700300555100_B46","doi-asserted-by":"crossref","unstructured":"Luzzi GA. Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management. J Eur Acad Dermatol Venereol\u20082002; 16: 253\u20136.","DOI":"10.1046\/j.1468-3083.2002.00481.x"},{"key":"2022061700300555100_B47","doi-asserted-by":"crossref","unstructured":"Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis\/chronic pelvic pain syndrome. Annu Rev Med\u20082006; 57: 195\u2013206.","DOI":"10.1146\/annurev.med.57.011205.135654"},{"key":"2022061700300555100_B48","doi-asserted-by":"crossref","unstructured":"Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Gao SY, Calhoun EA. Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. J Urol\u20082005; 174: 2319\u201322.","DOI":"10.1097\/01.ju.0000182152.28519.e7"},{"key":"2022061700300555100_B49","doi-asserted-by":"crossref","unstructured":"Ullrich PM, Turner JA, Ciol M, Berger R. Stress is associated with subsequent pain and disability among men with nonbacterial prostatitis\/pelvic pain. Ann Behav Med\u20082005; 30: 112\u20138.","DOI":"10.1207\/s15324796abm3002_3"},{"key":"2022061700300555100_B50","doi-asserted-by":"crossref","unstructured":"Hedelin H, Jonsson K. Chronic prostatitis\/chronic pelvic pain syndrome: symptoms are aggravated by cold and become less distressing with age and time. Scand J Urol Nephrol\u20082007; 41: 516\u201320.","DOI":"10.1080\/00365590701428517"},{"key":"2022061700300555100_B51","doi-asserted-by":"crossref","unstructured":"Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol\u20082004; 46: 760\u20134.","DOI":"10.1016\/j.eururo.2004.08.003"},{"key":"2022061700300555100_B52","doi-asserted-by":"crossref","unstructured":"Kasper S. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem\u20082005; 94: 279\u201397.","DOI":"10.1002\/jcb.20339"},{"key":"2022061700300555100_B53","doi-asserted-by":"crossref","unstructured":"Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell\u20082003; 4: 223\u201338.","DOI":"10.1016\/S1535-6108(03)00197-1"},{"key":"2022061700300555100_B54","doi-asserted-by":"crossref","unstructured":"Lopez-Lago M, Lee H, Cruz C, Movilla N, Bustelo XR. Tyrosine phosphorylation mediates both activation and down-modulation of the biological activity of Vav. Mol Cell Biol\u20082000; 20: 1678\u201391.","DOI":"10.1128\/MCB.20.5.1678-1691.2000"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/15\/6396\/2592946\/6396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/15\/6396\/2592946\/6396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T08:08:41Z","timestamp":1684483721000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/15\/6396\/540760\/Targeted-Overexpression-of-Vav3-Oncogene-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":54,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2008,8,1]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0645","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22376177","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376177.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376171.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376180.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376174.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376180","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376171","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376174","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6498122.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498122","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}